In particular, our study points to MCT4 as a potential therapeutic target in AML patients and to its inhibitor SYRO as a new anti-proliferative drug and inducer of autophagy, to be used in combination with conventional chemotherapeutic agents in AML treatment. This evidence concerns the gene SLC16A3 and acute myeloid leukemia.